What Is the True Number Needed to Screen and Treat to Save a Life With Prostate-Specific Antigen Testing?
- 1 February 2011
- journal article
- statistics in-oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 464-467
- https://doi.org/10.1200/jco.2010.30.6373
Abstract
Purpose The European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 20% mortality reduction with prostate-specific antigen (PSA) screening. However, they estimated a number needed to screen (NNS) of 1,410 and a number needed to treat (NNT) of 48 to prevent one prostate cancer death at 9 years. Although NNS and NNT are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the ERSPC, NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. Our objective was to re-examine the effect of varying follow-up times on NNS and NNT using data extrapolated from the ERSPC report. Materials and Methods On the basis of published ERSPC data, we modeled the cumulative hazard function using a piecewise exponential model, assuming a constant hazard of 0.0002 for the screening and control groups for years 1 to 7 of the trial and different constant rates of 0.00062 and 0.00102 for the screening and...Keywords
This publication has 20 references indexed in Scilit:
- Risk Factors for Prostate Cancer Detection After a Negative Biopsy: A Novel Multivariable Longitudinal ApproachJournal of Clinical Oncology, 2010
- Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005JNCI Journal of the National Cancer Institute, 2009
- Calculation of Number Needed to TreatNew England Journal of Medicine, 2009
- Screening for Prostate Cancer — The Controversy That Refuses to DieNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Calculation of NNTs in RCTs with time-to-event outcomes: A literature reviewBMC Medical Research Methodology, 2009
- Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized TrialJNCI Journal of the National Cancer Institute, 2008
- Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortalityBJU International, 2008
- Quantifying the role of PSA screening in the US prostate cancer mortality declineCancer Causes & Control, 2007
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988